New hepatitis C therapies for special patient populations

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 2, 2016, Pages 217-229

  Soriano, Vincent ^a   Labarga, Pablo ^b   De Mendoza, Carmen ^c   Fernández Montero, José V ^d   Esposito, Isabella ^a   Benítez Gutiérrez, Laura ^c   Peña, José M ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Madrid 28035 ^*  (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Daclatasvir; HCV; Hepatitis B; HIV; Kidney insufficiency; Paritaprevir; Simeprevir; Sofosbuvir; Transplantation

Indexed keywords

ABACAVIR; ASUNAPREVIR; ATAZANAVIR; DACLATASVIR; DARUNAVIR; DASABUVIR; DOLUTEGRAVIR; EFAVIRENZ; ELBASVIR; ELVITEGRAVIR; EMTRICITABINE; GRAZOPREVIR; LAMIVUDINE; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RALTEGRAVIR; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER PATIENT; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DRUG DEPENDENCE; DRUG EXPOSURE; GENOTYPE; GERIATRIC PATIENT; GRAFT RECIPIENT; HEMODIALYSIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICATION COMPLIANCE; MIXED INFECTION; OBESITY; PATIENT CODING; PEDIATRICS; PREGNANT WOMAN; REINFECTION; REVIEW; SOCIAL ASPECT; TREATMENT FAILURE; COMPLICATION; DRUG INTERACTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SUBSTANCE ABUSE; TRANSMISSION;

ANTIVIRAL AGENTS; COINFECTION; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RENAL INSUFFICIENCY; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84957438363     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1112790     Document Type: Review

References (124)

1. Thomas D. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013; 19: 850-858.
2. Gower E, Estes C, Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61 (suppl): 45-57.
3. CDC. Hepatitis C information. 2015 [cited 2015 Sep]. Available at: www.cc.gov/hepatitis/HCV
4. EASL. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60: 392-420.
5. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002; 8 (suppl 10): S14-8.
6. EASL. Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015; 63: 199-236.
7. Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol. 2013; 9: 5-16.
8. Gentile I, Buonomo A, Zappulo E., et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus free world? Expert Rev Anti Infect Ther. 2014; 12: 763-773.
9. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 1176-1192.
10. Conjeevaram H. Continued progress against hepatitis C infection. JAMA. 2015; 313: 1716-1717.
11. Muir A, Naggie S. HCV treatment: is it possible to cure all HCV patients? Clin Gastroenterol Hepatol. 2015; 13: 2166-2172.
12. Chtioui H, Buclin T, Moradpour D. New hepatitis C treatments: pharmacological considerations and potential for drug interactions. Rev Med Suisse. 2014; 10: 1600-1604.
13. Soriano V, Labarga P, Barreiro P., et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015; 11: 333-341.
14. Burger D, Back D, Buggisch P., et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013; 58: 792-800.
15. Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013; 10: 596-606.
16. Ahmad T, Yin P, Saffitz J., et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015; 62: 409-416.
17. Soriano V, Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev. 2015; 17: 121-122.
18. Karageorgopoulos D, El-Sherif O, Bhagani S., et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/HCV coinfection. Curr Opin Infect Dis. 2014; 27: 36-45.
19. Esposito I, Labarga P, Barreiro P., et al. Dual antiviral therapy for HIV and HCV-drug interactions and side effects. Expert Opin Drug Saf. 2015; 14: 1421-1434.
20. Tischer S, Fontana R. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014; 60: 872-884.
21. Toussaint-Miller K, Andres J. Treatment considerations for unique patients populations with HCV genotype 1 infection. Ann Pharmacother. 2015; 49: 1015-1030.
22. Gane E, Roberts S, Stedman C., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010; 376: 1467-1475.
23. Wiktor S. Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape. Hepatology. 2015; 62: 13-15.
24. Jensen D, OLeary J, Pockros P., et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 45]. Hepatology. 2014; 60 (suppl): 219A.
25. Dieterich D, Bacon B, Flamm S., et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 46]. Hepatology. 2014; 60 (suppl): 220A.
26. Ferenci P, Bernstein D, Lalezari J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370: 1983-1992.
27. Bourliere M, Sulkowski M, Omata M., et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. AASLD 2014, Boston, MA [abstract 82]. Hepatology. 2014; 60 (suppl): 239A.
28. Hézode C, Asselah T, Reddy K., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015; 385: 2502-2509.
29. Lawitz E, Gane E, Pearlman B., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1075-1086.
30. Poordad F, Sievert W, Mollison L., et al. Fixed-dose combination therapy with daclatasvir, asunaprevir and beclabuvir for non-cirrhotic patients with HCV genotype 1 infection. JAMA. 2015; 313: 1728-1735.
31. Muir A, Poordad F, Lalezari J., et al. Daclatasvir in combination with asunaprevir and beclabusvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015; 313: 1736-1744.
32. Hassanein T, Sims K, Bennett M., et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabusvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015; 62: 1204-1206.
33. Treviño A, De Mendoza C, Parra P., et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011; 16: 413-416.
34. Poveda E, Wyles D, Mena A., et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014; 108: 181-191.
35. Nguyen L, Gray E, Dean J., et al Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Antivir Ther. 2015 Apr 29. DOI: 10.3851/IMP2964. [Epub ahead of print].
36. Barreiro P, Fernandez-Montero JV, De Mendoza C., et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res. 2014; 105: 1-7.
37. Jiménez-Nácher I, Alvarez E, Morello J., et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol. 2011; 7: 457-477.
38. You D, Pockros P. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013; 14: 2581-2589.
39. Gentile I, Borgia F, Buonomo A., et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014; 21: 3261-3270.
40. Sofia M. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antivir Res. 2014; 107: 119-124.
41. Soriano V, Vispo E, De Mendoza C., et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013; 14: 1161-1170.
42. Labarga P, Barreiro P, Martin-Carbonero L., et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009; 23: 689-696.
43. Rockstroh J, Puoti M, Rodriguez-Torres M., et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1-4 infection: the PHOTON-1 and -2 trials. AASLD 2014, Boston, MA [abstract 195]. Hepatology. 2014; 60 (suppl): 295A.
44. Osinusi A, Townsend K, Kohli A., et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection. JAMA. 2015; 313: 1232-1239.
45. Gentile I, Buonomo A, Borgia F., et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014; 23: 561-571.
46. Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2015; 64: 860-862.
47. Wyles D, Ruane P, Sulkowski M., et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373: 714-725.
48. Naggie S, Cooper C, Saag M., et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373: 705-713.
49. Sulkowski M, Eron J, Wyles D., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313: 1223-1231.
50. Piroth L, Paniez H, Taburet A., et al. High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced, null-responder patients with HIV/HCV genotypes 1-4 coinfection: the ANRS HC30 QUADRIH study. Clin Infect Dis. 2015; 61: 817-825.
51. Sulkowski M, Hezode C, Gerstoft J., et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385: 1087-1097.
52. Stock P, Terrault N. HIV and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015; 61: 1747-1754.
53. Kwo P, Badshah M. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage liver disease. Curr Opin Organ Transplant. 2015; 20: 235-241.
54. Pellicelli A, Montalbano M, Lionetti R., et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014; 46: 923-927.
55. Kwo P, Mantry P, Coakley E., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014; 371: 2375-2382.
56. Menon R, Badri P, Wang T., et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015; 63: 20-29.
57. Stine J, Intagliata N, Shah N., et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015; 60: 1031-1035.
58. Soriano V, Barreiro P, De Mendoza C., et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2015 Jun 4. DOI: 10.3851/IMP2969. [Epub ahead of print].
59. Charlton M, Everson G, Flamm S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015; 149: 649-659.
60. Poole R. Daclatasvir + Asunaprevir: first global approval. Drugs. 2014; 74: 1559-1571.
61. Dyson J, Hutchinson J, Harrison L., et al Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00589-9. DOI: 10.1016/j.jhep.2015.07.041. [Epub ahead of print].
62. Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin solve the need for treatment? J Hepatol. 2014; 61: 1430-1433.
63. Ferenci P, Kozbial K, Mandorfer M., et al. HCV targeting of patients with cirrhosis. J Hepatol. 2015; 63: 1015-1022.
64. Saxena V, Nyberg L, Pauly M., et al. Safety and Efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology. 2015; 62: 715-725.
65. Jacobson I, Poordad F, Firpi-Morell R., et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh B cirrhosis (C-SALT part A). EASL, Vienna, Austria [abstract O008]. J Hepatol. 2015; 62 (suppl): 193-194.
66. Poordad F, Schiff E, Vierling J., et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or postransplant recurrence: phase 3 ALLY-1 study. EASL, Vienna, Austria [abstract L08]. J Hepatol. 2015; 62 (suppl): 261.
67. Gentile I, Buonomo A, Borgia G. Dasabuvir: A non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials. 2014; 9: 115-123.
68. Khatri A, Dutta S, Marbury T., et al. The pharmacokinetics and safety of the DAA ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. AASLD 2014, Boston, MA [abstract 238]. Hepatology. 2014; 60 (suppl): 320A.
69. Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014; 15: 2609-2622.
70. Gentile I, Buonomo A, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014; 12: 1033-1043.
71. Roth D, Nelson D, Bruchfeld A., et al. C-SURFER: Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patient with HCV genotype 1 infection and chronic kidney disease. EASL, Vienna, Austria [abstract LP02]. J Hepatol. 2015; 62 (suppl): 263-264.
72. Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014; 20: 14559-14567.
73. Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012; 26: 517-530.
74. Zhou J, Dore G, Zhang F., et al. Hepatitis B and C virus coinfection in the TREAT Asia Observational database. J Gastroenterol Hepatol. 2007; 22: 1510-1518.
75. Pontisso P, Ruvoletto M, Fattovich G., et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993; 105: 1529-1533.
76. Chu C, Lee S. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008; 23: 512-520.
77. Soriano V, Barreiro P, Martin-Carbonero L., et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007; 195: 1181-1183.
78. Liu C, Chen P, Lai M., et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003; 37: 568-576.
79. Liu C, Chuang W, Lee C., et al. Peginterferon alfa-2b plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009; 136: 496-504.
80. Collins J, Raphael K, Terry C., et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis. 2015; 61: 1304-1306.
81. Wahle R, Perez R, Pereira P., et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis. 2015;19:533-537.
82. Soriano V, Labarga P, De Mendoza C., et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015; 12: 344-352.
83. Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013; 10: 568-569.
84. Robaeys G, Grebely J, Mauss S., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013; 57 (suppl 2): 129-137.
85. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009; 49: 561-573.
86. Paraskevis D, Nikolopoulos G, Fotiou A., et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One. 2013; 8 (e78941):1.
87. Strathdee S, Beyrer C. Threading the needle-how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015; 373: 397-399.
88. Soriano V, Sherman K, Rockstroh J., et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. Aids. 2011; 25: 2197-2208.
89. Altice F, Kamarulzaman A, Soriano V., et al. Treatment of medical, psychiatric, and substance use comorbidities in people infected with HIV who use drugs. Lancet. 2010; 376: 367-387.
90. Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012; 142: 1324-1334.
91. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012; 61 (suppl 1): 47-58.
92. Pineda JA, Nuñez-Torres R, Tellez F., et al. HCV reinfection after sustained virological response in HIV-infected patient with chronic hepatitis C. J Infect. 2015 Jul 23. pii: S0163-4453(15)00231-5. DOI: 10.1016/j.jinf.2015.07.006. [Epub ahead of print].
93. Svarovskaia E, Martin R, Chodavarapu K., et al. HCV reinfection cases in phase 3 studies of sofosbuvir. EASL, Vienna, Austria [abstract O063]. J Hepatol. 2015; 62 (suppl): 222-223.
94. Soriano V, Labarga P, De Mendoza C., et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2015 May 2. DOI: 10.1111/liv.12858. [Epub ahead of print].
95. Martin T, Martin N, Hickman M., et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids. 2013; 27: 2551-2557.
96. Melin P, Chousterman M, Fontanges T., et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010; 22: 1050-1057.
97. Gallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev. 2011; 13: 171-179.
98. Soriano V, Vispo E, Poveda E., et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother. 2012; 13: 313-323.
99. Barreiro P, Labarga P, Fernandez-Montero JV., et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol. 2015; 71: 63-66.
100. Krishnan P, Tripathi R, Schnell G., et al. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother. 2015; 59: 5445-5454.
101. Hedskog C, Dvory-Sobol H, Gontcharova V., et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22:871-881.
102. Yoshimi S, Imamura M, Murakami E., et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015; 87: 1913-1920.
103. Krishnan P, Tripathi R, Schnell G., et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir and dasabuvir-based regimens. EASL, Vienna, Austria [abstract O057]. J Hepatol. 2015; 62 (suppl): 220.
104. Dvory-Sobol H, Wyles D, Ouyang W., et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. EASL, Vienna, Austria [abstract O059]. J Hepatol. 2015; 62 (suppl): 221.
105. Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00552-8. DOI: 10.1016/j.jhep.2015.08.010. [Epub ahead of print].
106. Osinusi A, Kohli A, Marti M., et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014; 161: 634-638.
107. Lawitz E, Flamm S, Yang J., et al. Re-treatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL, Vienna, Austria [abstract O005]. J Hepatol. 2015; 62 (suppl): 192.
108. Ogawa E, Furusyo N, Dohmen K., et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015; 22: 992-1001.
109. Sherman A, Sherman K. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep. 2015 Sep; 12 (3): 353-361.
110. Soriano V, Labarga P, Fernandez-Montero JV., et al. Hepatitis C cure with antiviral therapy-benefits beyond the liver. Antivir Ther. 2015 Jun 25. DOI: 10.3851/IMP2975. [Epub ahead of print].
111. Negro F, Forton D, Craxi A., et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Aug 28. pii: S0016-5085(15)01203-2. DOI: 10.1053/j.gastro.2015.08.035. [Epub ahead of print].
112. Iorio R, Giannattasio A, Sepe A., et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41: 1431-1437.
113. Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol. 2014; 20: 15965-15974.
114. Beste L, Bondurant H, Ioannou G. Prevalence and management of chronic hepatitis C virus infection in women. Med Clin N Am. 2015; 99: 575-586.
115. Roberts S, Miller R, Jones J., et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol. 2010; 88: 551-559.
116. Vespasiani-Gentilucci U, Galati G, Gallo P., et al. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015; 21: 7412-7426.
117. Renet S, Chaumais MC, Antonini T., et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015 Aug 4. pii: S0016-5085(15)01083-5. DOI: 10.1053/j.gastro.2015.07.051. [Epub ahead of print].
118. Soriano V, Barreiro P, De Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2015 Aug 27. DOI: 10.1002/hep.28137. [Epub ahead of print].
119. Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2015; 15: 787-800.
120. Everhart J, Lok A, Kim H., et al. Weight-related effects on disease progression in the HALT-C trial. Gastroenterology. 2009; 137: 549-557.
121. Afdhal N, Zeuzem S, Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1889-1898.
122. Franco S, Tural C, Nevot M., et al. Detection of a sexually transmitted HCV protease inhibitor-resistance variant in a HIV-infected homosexual man. Gastroenterology. 2014; 147: 599-601.
123. Arends J, Lieveld F, Boeijen L., et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254-1262.
124. Najafzadeh M, Andersson K, Shrank W., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015; 162: 407-419.